Company earns number two ranking in CenterWatch's European site survey
WILMINGTON, N.C. (June 11, 2010) - PPD, Inc. (Nasdaq: PPDI) today announced it has been rated one of Europe's top contract research organizations (CROs) in the 2010 CenterWatch European Site Survey. The company earned a number two ranking among CROs with 78.4 percent of participants rating PPD's overall relationship quality as "excellent" or "good."
PPD scored among the top three in 26 of the 29 survey attributes and received the highest marks of any CRO for being organized and prepared, an attribute considered important for clinical trial study success. PPD also rated highest for its work style and supportive culture and scored well in study initiation and ongoing conduct, staff professionalism and grant payment process.
"We value our strong, collaborative relationships with investigative sites across the globe and consider them our partners in drug development," said Sebastian Pacios, M.D., senior vice president of clinical development for Europe, Middle East and Africa. "Through our specialized project teams, we work closely with investigators to recruit the right patients and deliver accurate, reliable study data for our clients."
Nearly 1,000 respondents from 30 countries completed the survey, which was conducted this past January through March. Principal investigators comprised 77 percent of respondents while 13 percent were sub-investigators, and the remaining responses were study coordinators and nurses.
The survey is conducted by CenterWatch, a leading publishing and information services company focused on the clinical trials industry. The European survey is conducted every two years and includes input from clinical research professionals at biopharmaceutical companies, CROs and investigative sites.
PPD is a leading global contract research organization, celebrating 25 years of providing drug discovery, development and lifecycle management services. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 41 countries and more than 10,500 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a commitment to quality to help clients and partners accelerate the delivery of safe and effective therapeutics and maximize the returns on their R&D investments. For more information, visit www.ppdi.com.
Except for historical information, all of the statements, expectations and assumptions contained in this news release, including expectations and assumptions about PPD's rating in the 2010 CenterWatch European Site Survey, are forward-looking statements that involve a number of risks and uncertainties. Although PPD attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. In addition, other important factors which could cause results to differ materially include the following: dependence on collaborative relationships, including relationships with investigative sites; competition in the outsourcing industry; rapid technological advances that make our services less competitive; success in sales growth; loss of large contracts; increased cancellation rates; economic conditions and outsourcing trends in the pharmaceutical, biotechnology, medical device, academic and government industry segments; the ability to attract and retain key personnel; risks associated with acquisitions and investments, such as impairments; and the other risk factors set forth from time to time in the SEC filings for PPD, copies of which are available free of charge upon request from the PPD investor relations department.
Sue Ann Pentecost
+1 919 456 5890
+1 910 558 7585